Journal of Clinical Oncology
Articles in this Issue
The prognostic and predictive role of FDG PET/CT in melanoma patients treated with immune checkpoint blockade: A meta-analysis.
9542 Background: Immune checkpoint blockade (ICB) is standard therapy for advanced melanoma, but many patients derive limi...
A randomized, active-controlled phase 3 study of ivonescimab + FOLFOX versus bevacizumab + FOLFOX as first-line treatment of metastatic colorectal cancer (mCRC): HARMONi-GI3.
TPS3682 Background: Fluorouracil (5-FU)-based chemotherapy plus an anti–vascular endothelial growth factor (VEGF) or anti–...
Health shocks and advance care planning among U.S. older adults: Evidence from HRS 2012-2022.
11093 Background: Advance care planning (ACP) allows individuals to discuss and document preferences for future medical ca...
Regional trends in esophageal cancer burden across Africa, 1990–2023: A Global Burden of Disease study.
e16042 Background: Esophageal cancer is a major contributor to cancer-related mortality in Africa, with marked regional di...
Long term follow up of multiple myeloma patients achieving MRD negativity at 10 <sup>-6</sup> .
e19549 Background: Achievement of deep responses in multiple myeloma (MM) has been associated with improved outcome and th...
Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: Real-world evidence from the SOGUG-NIADY study of the Spanish Oncology Genitourinary Group (SOGUG).
4606 Background: Adjuvant nivolumab significantly improved disease-free survival (DFS) in patients (pts) with high-risk mu...
Early-onset colorectal cancer in a developing region: A five-year real-world analysis from Brazil.
e15704 Background: Numerous studies have reported a rising incidence of cancer among young adults worldwide, particularly...
Outcomes of frailty among hospitalized patients with acute myeloid leukemia: A National Inpatient Sample analysis (2017–2022).
e18520 Background: Frailty is increasingly recognized as an important determinant of outcomes in patients with hematologic...
RAISIC-1: A phase 1/2 clinical trial of the GPR65 inhibitor PTT-4256—Preliminary safety, tolerability, pharmacokinetic, and pharmacodynamic results.
2608 Background: The acidic tumor micro-environment is linked to immune suppression and insensitivity to immunotherapy. Th...
Triple-negative oligometastatic breast cancer: A retrospective cohort.
e13000 Background: The optimal management of oligometastatic breast cancer (OMBC) remains undefined. Given its bio...
ASCEND: A phase 1/2, dose-escalation, optimization, and dose-expansion study to evaluate the safety and antitumor activity of CR-001 in adults with locally advanced or metastatic solid tumors.
TPS2693 Background: CR-001 is a tetravalent bispecific antibody targeting anti-programmed cell death-1 (PD-1) and vascular...
Predictors of in-hospital mortality in chemotherapy-associated cardiomyopathy: A national inpatient sample analysis (2018-2022).
e24025 Background: Chemotherapy-associated cardiomyopathy (CAC) is a recognized complication of cancer treatment, yet pred...
Plasminogen activation system indices in basal cell carcinoma.
e21559 Background: The plasminogen activation system plays a key role in maintaining tissue homeostasis, participating in...
First-in-human results with IMA401, a MAGEA4/8-targeted T-cell receptor–based bispecific T-cell engager (TCER) in recurrent or refractory solid tumors.
2507 Background: IMA401 is a next-gen bispecific TCR-based T-cell engager designed to redirect T cells to antigen-positive...
Cohort-level safety and efficacy results for [ <sup>212</sup> Pb]VMT-α-NET in advanced somatostatin receptor subtype 2 (SSTR2+)–expressing neuroendocrine tumors (NETs): Cohorts 1–3.
4173 Background: [ 212 Pb]VMT-α-NET is an alpha-particle radiation-delivering agen...
Longitudinal changes in patient-reported quality of life (QOL) and hope among early phase cancer clinical trial (EPCT) participants.
11015 Background: Few studies have explored associations of longitudinal changes in patient-reported outcomes (PROs) and c...
A phase 1 study of HWK-007, a next-generation, protein tyrosine kinase 7 (PTK7)–targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors.
TPS3156 Background: PTK7 is a pseudokinase expressed during embryogenesis and downregulated in normal adult tissue. Aberra...
AI-based volumetric vs bidimensional RANO 2.0 progression assessment: Prognostic value for overall survival in glioblastoma.
e14099 Background: Glioblastoma (GBM) presents unique imaging challenges due to irregular morphology. The RANO 2.0 criteri...
Efficacy and safety of donafenib combined with TACE and with/without PD-(L)1 inhibitors for unresectable hepatocellular carcinoma (uHCC): A multicenter retrospective study.
e16212 Background: Donafenib(Dona) have shown superiority over sorafenib in improving OS and has favorable safety and tole...
A multicenter, randomized controlled phase III trial of TPF induction chemotherapy versus PF adjuvant chemotherapy combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: Long-term follow-up analysis.
6100 Background: To investigate whether TPF induction chemotherapy combined with concurrent chemoradiotherapy (CCRT) can p...
Gabapentin plus intranasal ketamine for the prevention and treatment of pain in patients undergoing radiotherapy for head and neck cancer: Phase II trial results.
12135 Background: Prophylactic gabapentin decreases pain, opioid use, and weight loss in head and neck (HNC) patients trea...
Difference-in-differences analysis of age-specific survival gains in acute myeloid leukemia following venetoclax approval.
e23058 Background: Venetoclax in combination with a hypomethylating agent or low-dose cytarabine received accelerated appr...
Outcomes of osimertinib rechallenge after osimertinib-induced interstitial lung disease in metastatic EGFR-mutated NSCLC: Systematic review and meta-analysis.
e20732 Background: Osimertinib is standard therapy for metastatic EGFR-mutated (mEGFR+) NSCLC but rarely causes pneumoniti...
Correlation between <i>CARINH</i> expression and clinical outcomes in metastatic clear-cell renal cell carcinoma (mccRCC).
4553 Background: CARINH is an interferon (IFN)-responsive long non-coding RNA that promotes...
Organ preservation strategy using dostarlimab for dMMR/MSI-H resectable solid tumors with whole-genome–based MRD monitoring (D-CURE: EPOC2401).
TPS2697 Background: Mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) solid tumors accumulate numer...